Date Title Description PDF
07 Nov 2024 On P&L The Company releases the press release related to the first nine months 2024 financial results Download
07 Nov 2024 On P&L The Company releases the first nine months 2024 financial results presentation Download
24 Oct 2024 On corporate transactions ROVI completes the strategic review of its CDMO business Download
31 Jul 2024 On P&L The Company releases the press release related to the first half 2024 financial results Download
31 Jul 2024 On P&L The Company releases the first half 2024 financial results presentation Download

Pages

Date Title Description PDF
24 Feb 2021 Annual Corporate Governance Report ROVI releases the 2020 Annual Corporate Governance Report Download
24 Feb 2021 Annual Report regarding remuneration of the members of the Board of Directors ROVI releases the 2020 annual report regarding remuneration of the members of the Board of Directors  Download
11 Jan 2021 Liquidity contracts and specialists Liquidity contract: transactions conducted in the fourth quarter of 2020 Download
24 Nov 2020 On business and financial situation The Company releases the presentation related to its strategy update because of the 2020 Capital Markets Day. Download
13 Nov 2020 Other relevant information The Company informs about the dividends payment  Download

Pages

Date Title Description PDF
08 Jan 2018 Contratos de liquidez y contrapartida Liquidity contract: transactions conducted in the fourth quarter of 2017 Download
21 Dec 2017 Préstamos, créditos y avales ROVI and the EIB agree to sign a loan to boost research into drug administration and prolonged-release technologies Download
08 Nov 2017 Información sobre Resultados ROVI releases the press release related to the nine-month period ended 30 September 2017 results Download
08 Nov 2017 Información sobre Resultados ROVI releases the presentation related to the nine-month period ended 30 September 2017 results. Download
24 Oct 2017 Otros sobre negocio y situación financiera The Company releases the presentation related to the update of its Phase III-Prima 3 Risperidone ISM® project. Download

Pages